GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 30-May-2025.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of GlaxoSmithKline Pharmaceuticals has approved audited standalone and consolidated financial results for Q4 and FY25 (year ended March 31, 2025). Standalone revenue from operations rose to Rs. 3,72,349 lakhs (from Rs. 3,40,725 lakhs in FY24), with profit for the year jumping to Rs. 91,906 lakhs (from Rs. 58,469 lakhs). The Board has recommended a final dividend of Rs. 42 per equity share (face value Rs. 10), up 31% from Rs. 32 paid for FY24. The record date for dividend eligibility is fixed as May 30, 2025, with the 100th AGM scheduled for June 27, 2025, and dividend payment from June 30, 2025. Additionally, Dr. Sunita Maheshwari has been re-appointed as Independent Director for a second 3-year term, and Parikh & Associates has been appointed as Secretarial Auditor for 5 years (FY26 to FY30).
A 31% hike in the final dividend signals strong cash generation and a shareholder-friendly stance, likely to support the stock sentiment around the record date. Sharp profit growth (standalone PAT up ~57% YoY) driven by better operating leverage and absence of prior-year VRS-related exceptional charges reinforces a positive earnings outlook.